cGAS cuts both ways — and reprogramming reaches the clinic
The sharpest mechanistic story this cycle is cGAS as a double-edged enzyme: a Nature Aging paper shows senescent human cells actively export nuclear R-loops to ignite cGAS-STING and the SASP, while a comparative-biology result explains how the naked mole-rat rewires the same enzyme to boost DNA repair instead. On the translational side, partial epigenetic reprogramming crossed into humans (Life Biosciences' ER-100 first dosing) and drew nine figures of fresh capital (NewLimit), though both are milestones, not data. The needed counterweight: a peer-reviewed result showing senolytics do NOT reverse DNA-methylation senescence signatures — a caution that methylation clocks may not register the interventions we expect them to.
of age-related muscle molecular differences absent in trained older adults (Nature Aging 2026)
Where the human evidence is
Count by statusEvidence-stage map
Evidence stage × investigator promise (1–10)DNA damage, cGAS-STING & inflammaging
Senescent cells export R-loops via DDX1–XPO1 to fire cGAS-STING and drive the SASP
Hao et al. show nuclear-derived R-loops (enriched in alpha-satellite repeats) accumulate in the cytoplasm of senescent cells, localize into cytoplasmic chromatin fragments, and activate cGAS-STING to drive the SASP and inflammaging. The exportin-1 (XPO1)–DEAD-box helicase 1 (DDX1) complex is required for this nuclear export; XPO1 inhibition blocked R-loop export, reduced inflammaging and extended healthspan in mice. A clean, druggable mechanistic node linking genome instability to the innate-immune arm of aging — note the healthspan data are murine.
Read the paperComparative anchor: naked mole-rat cGAS potentiates DNA repair instead of suppressing it
Included as context for the item above: four amino-acid substitutions in naked mole-rat cGAS reduce its ubiquitination/degradation, so the protein persists after DNA damage and strengthens interactions with FANCI and RAD50 to boost homologous-recombination repair — the opposite of cGAS's repair-suppressing role in humans. Fruit flies engineered with the four mole-rat residues lived longer. Frames the therapeutic-window question: can we damp the cGAS-STING inflammaging axis without losing genome-maintenance benefit? Published Oct 2025, not this week — carried as a mechanistic pairing.
Read the paperPartial reprogramming reaches humans (milestones, not data)
Life Biosciences doses first human with partial epigenetic reprogramming (ER-100)
First-ever administration of a partial epigenetic reprogramming therapy to a human. ER-100 uses controlled OCT4/SOX2/KLF4 (OSK) expression delivered to one eye and activated by systemic doxycycline for eight weeks, targeting optic neuropathies (open-angle glaucoma and NAION). The Phase 1 (up to 18 participants, four sites) is a safety/tolerability study; initial data are expected late 2026–early 2027. This is a translational milestone only — treat as an early signal, not evidence of clock reversal.
Read the paperNewLimit raises $435M Series C to push liver-cell reprogramming toward human trials
Founders Fund–led round (with Lilly Ventures, Kleiner Perkins and others) at a ~$3.1B valuation; ~$760M raised to date. NewLimit reports a prototype LNP-delivered RNA medicine that transiently expresses transcription-factor combinations and reverses cell age in old human liver cells, with first-in-human trials targeted for next year. Capital and preclinical claim only — no peer-reviewed human efficacy. Notable as a read on how fast reprogramming is being capitalized.
Read the paper